Publications

PubMed Publications

https://www.ncbi.nlm.nih.gov/pubmed/?term=orsulic+s

 

Cover Images

Journal cover photos Orsulic, Sandra

Selected Publications

Nallanthighal S, Rada M, Heiserman JP, Cha J, Sage J, Zhou B, Yang W, Hu Y, Korgaonkar C, Hanos CT, Ashkavand Z, Norman K, Orsulic S, Cheon DJ. Inhibition of collagen XI alpha 1-induced fatty acid oxidation triggers apoptotic cell death in cisplatin-resistant ovarian cancer. Cell Death Dis. 2020 Apr 20;11(4):258. doi: 10.1038/s41419-020-2442-z. https://www.ncbi.nlm.nih.gov/pubmed/32312965

Orsulic S, Karlan BY. Can molecular subtyping be used to triage women with advanced ovarian cancer to Primary Debulking Surgery or Neoadjuvant Chemotherapy? Gynecol Oncol. 2019 Feb;152(2):221-222. https://www.ncbi.nlm.nih.gov/pubmed/30704616

Haro M, Orsulic S. A Paradoxical Correlation of Cancer-Associated Fibroblasts With Survival Outcomes in B-Cell Lymphomas and Carcinomas. Front Cell Dev Biol. 2018 Aug 28;6:98. https://www.ncbi.nlm.nih.gov/pubmed/30211161

Jia D, Nagaoka Y, Katsumata M, Orsulic S. Inflammation is a key contributor to ovarian cancer cell seeding. Sci Rep. 2018 Aug 17;8(1):12394. https://www.ncbi.nlm.nih.gov/pubmed/30120290

Rada M, Nallanthighal S, Cha J, Ryan K, Sage J, Eldred C, Ullo M, Orsulic S, Cheon DJ. Inhibitor of apoptosis proteins (IAPs) mediate collagen type XI alpha 1-driven cisplatin resistance in ovarian cancer. Oncogene. 2018 Aug;37(35):4809-4820. https://www.ncbi.nlm.nih.gov/pubmed/29769618

Berger AC, Korkut A, Kanchi RS, Hegde AM, Lenoir W, Liu W, Liu Y, Fan H, Shen H, Ravikumar V, Rao A, Schultz A, Li X, Sumazin P, Williams C, Mestdagh P, Gunaratne PH, Yau C, Bowlby R, Robertson AG, Tiezzi DG, Wang C, Cherniack AD, Godwin AK, Kuderer NM, Rader JS, Zuna RE, Sood AK, Lazar AJ, Ojesina AI, Adebamowo C, Adebamowo SN, Baggerly KA, Chen TW, Chiu HS, Lefever S, Liu L, MacKenzie K, Orsulic S, Roszik J, Shelley CS, Song Q, Vellano CP, Wentzensen N; Cancer Genome Atlas Research Network, Weinstein JN, Mills GB, Levine DA, Akbani R. A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers. Cancer Cell. 2018 Apr 9;33(4):690-705. https://www.ncbi.nlm.nih.gov/pubmed/29622464

Watanabe T, Marotta M, Suzuki R, Diede SJ, Tapscott SJ, Niida A, Chen X, Mouakkad L, Kondratova A, Giuliano AE, Orsulic S, Tanaka H. Impediment of replication forks by long non-coding RNA provokes chromosomal rearrangements by error-prone restart. Cell Rep. 2017 Nov 21; 21(8):2223-2235. https://www.ncbi.nlm.nih.gov/pubmed/29166612

Jia D, Liu Z, Deng N, Tan TZ, Huang RY, Taylor-Harding B, Cheon DJ, Lawrenson K, Wiedemeyer WR, Walts AE, Karlan BY, Orsulic S. A COL11A1-correlated pan-cancer gene signature of activated fibroblasts for the prioritization of therapeutic targets. Cancer Lett. 2016 Nov 28;382(2):203-214. https://www.ncbi.nlm.nih.gov/pubmed/27609069

Gozo MC, Jia D, Aspuria PJ, Cheon DJ, Miura N, Walts AE, Karlan BY, Orsulic S. FOXC2 augments tumor propagation and metastasis in osteosarcoma. Oncotarget. 2016 Oct 18;7(42):68792-68802. https://www.ncbi.nlm.nih.gov/pubmed/27634875

Beach JA, Aspuria PJ, Cheon DJ, Lawrenson K, Agadjanian H, Walsh CS, Karlan BY, Orsulic S. Sphingosine kinase 1 is required for TGF-β mediated fibroblast-to-myofibroblast differentiation in ovarian cancer. Oncotarget. 2016 Jan 26;7(4):4167-4182. https://www.ncbi.nlm.nih.gov/pubmed/26716409

Liu Z, Beach JA, Agadjanian H, Jia D, Aspuria PJ, Karlan BY, Orsulic S. Suboptimal cytoreduction in ovarian carcinoma is associated with molecular pathways characteristic of increased stromal activation. Gynecol Oncol. 2015 Dec;139(3):394-400. https://www.ncbi.nlm.nih.gov/pubmed/26348314

Walts AE, Bomalaski JS, Ines D, Orsulic S. Argininosuccinate synthetase (ASS) deficiency in high-grade pulmonary neuroendocrine carcinoma: an opportunity for personalized targeted therapy. J Cancer Res Clin Oncol. 2015 Aug;141(8):1363-1369. https://www.ncbi.nlm.nih.gov/pubmed/25548129

Cheon DJ, Li AJ, Beach JA, Walts AE, Tran H, Lester J, Karlan BY, Orsulic S. ADAM12 is a prognostic factor associated with an aggressive molecular subtype of high-grade serous ovarian carcinoma. Carcinogenesis. 2015 Jul;36(7):739-747.  https://www.ncbi.nlm.nih.gov/pubmed/25926422

Aspuria PJ, Lunt SY, Väremo L, Vergnes L, Gozo M, Beach JA, Salumbides B, Reue K, Wiedemeyer WR, Nielsen J, Karlan BY, Orsulic S. Succinate dehydrogenase inhibition leads to epithelial-mesenchymal transition and reprogrammed carbon metabolism. Cancer Metab. 2014 Dec 15;2:21. https://www.ncbi.nlm.nih.gov/pubmed/25671108

Cheon DJ, Walts AE, Beach JA, Lester J, Bomalaski JS, Walsh CS, Ruprecht Wiedemeyer W, Karlan BY, Orsulic S. Differential expression of argininosuccinate synthetase in serous and non-serous ovarian carcinomas. J Pathol Clin Res. 2014 Nov 5;1(1):41-53. https://www.ncbi.nlm.nih.gov/pubmed/27499892

Cheon DJ, Tong Y, Sim MS, Dering J, Berel D, Cui X, Lester J, Beach JA, Tighiouart M, Walts AE, Karlan BY, Orsulic S. A collagen-remodeling gene signature regulated by TGF-β signaling is associated with metastasis and poor survival in serous ovarian cancer. Clin Cancer Res. 2014 Feb 1;20(3):711-723. https://www.ncbi.nlm.nih.gov/pubmed/24218511